| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3924785 | European Urology | 2014 | 11 Pages |
Abstract
It is a very exciting time in the field of mCRPC, where therapeutic advances have improved outcomes in this disease, although once metastatic overall median survival remains a dismal 2-3 years. The key now will be to understand how best to use these new agents, understand the mechanisms of resistance to them, continue to develop novel treatment strategies, and ultimately test these agents earlier in the disease when cure may be possible.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Srikala S. Sridhar, Stephen J. Freedland, Martin E. Gleave, Celestia Higano, Peter Mulders, Chris Parker, Oliver Sartor, Fred Saad,